Immune checkpoint inhibitor–associated scleroderma refractory to corticosteroids: Clinical improvement with intravenous immune globulin and dupilumab

JAAD Case Reports 2026 Open access

Read full text
Authors: Dema Abul-Enin, Nicole L. Edmonds, Corina A. Rusu
DOI: 10.1016/j.jdcr.2025.12.027
Cited by: 1
References: 9

Abstract

Scleroderma is an autoimmune disease characterized by increased production and deposition of collagen in the skin, which manifests as thickening and hardening of the skin. While the exact mechanism behind the disorder is unknown, few cases have been linked to immune-altering therapies, such as immune checkpoint inhibitors (ICIs).1 Here, we present the case of a woman who developed scleroderma after undergoing ICI therapy for mesothelioma.

Fields of Study & Subjects

Systemic Sclerosis and Related Diseases Cancer Immunotherapy and Biomarkers Inflammatory Myopathies and Dermatomyositis

Publication details

Journal / source
JAAD Case Reports
Publisher
Elsevier BV
Volume
70
Pages
249–252
Publication date
15 January 2026
Language
EN